PlaMitEng
Financiado
Plant mitochondrial genome engineering: technology development and application t...
Plant mitochondrial genome engineering: technology development and application to study fundamental aspects of mitochondrial gene expression
PlaMitEng has the highly ambitious overall objective to make the mitochondrial genome of seed plants amenable to genetic engineering. The project consists of two complementary work packages (WPs). In WP1, TALEN-GDM, a technology f...
PlaMitEng has the highly ambitious overall objective to make the mitochondrial genome of seed plants amenable to genetic engineering. The project consists of two complementary work packages (WPs). In WP1, TALEN-GDM, a technology for plant mitochondrial genome editing recently developed by us will be used to systematically study plant mitochondrial gene expression in vivo. The focus will be on translation initiation and translational regulation in mitochondria, the mechanisms of which are currently completely unknown. In WP2, PlaMitEng will develop a technology for direct genetic transformation of the plant mitochondrial genome. The mitochondrial genome is the only genome of the plant cell that, due to the lack of a mitochondrion-specific selection system, is not amenable to transformation and has remained recalcitrant to the insertion and expression of transgenes. Taking advantage of (i) our recent construction of a mitochondrion-specific selectable marker gene, (ii) the generation of a dedicated recipient line for mitochondrial transformation, and (iii) the design of a new transformation strategy (referred to as multivectorial transformation) that will enable the large-scale testing of expression elements for their suitability to drive the expression of mitochondrial transgenes in vivo, PlaMitEng will pursue the development of a robust technology for transformation of the plant mitochondrial genome. The possibility to express transgenes from plant mitochondrial genomes will open up entirely new opportunities in both basic and applied research, and pave the way to harnessing the enormous potential of mitochondrial biotechnology and synthetic biology.
ver más
Duración del proyecto: 59 meses
Fecha Inicio: 2024-07-01
Fecha Fin: 2029-06-30
Fecha Fin: 2029-06-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-07-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2023-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5